Briefs: Wanbury and Bafna Pharmaceuticals

Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API

Alembic Pharmaceuticals receives USFDA final approval for Albendazole Tablets USP, 200 mg

Emcure Pharmaceuticals launches solution for menopause wellness ‘Arth’ in India

Effective, holistic, science-backed targeted solutions for symptomatic treatment

DKSH partners with Hasten Biopharmaceutical’s growth in Thailand

Royal Sense launches multiple products in pharmaceutical category

Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale

Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical

CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases

IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr

The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24

Jagsonpal Pharmaceuticals Q1 FY25 revenues at Rs. 61.4 Crores, 41% growth over Q4 FY24

The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024

GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr

Strong topline growth driven by solid performance across key brands.